Peter Kiener - Sucampo Pharmaceuticals Chief Scientific Officer
Executive
Dr. Peter A. Kiener is a Chief Scientific Officer of the Company, since October 27, 2014. Prior to joining Sucampo, he served as CSO of Ambrx Inc., a clinicalstage biopharmaceutical company focused on the development of antibodydrug conjugates, since 2013. From 2009 to 2013, Dr. Kiener was President and Cofounder of Zyngenia Inc., an earlystage biopharmaceutical company. He also held leadership roles of increasing responsibility from 2001 to 2009 at MedImmune LLC, the global biologics arm of AstraZeneca, including Executive Vice President and Global Head of Biologics Research and Development, Senior Vice President and Head of Global Research, and Vice President of Research. Dr. Kiener worked on biologics for BristolMyers Squibb from 1983 to 2001. He started his career at the University of North TexasTexas College of Osteopathic Medicine, where he was an Assistant Professor from 1982 to 1983, and the University of Massachusetts at Amherst, where he was a Research Associate from 1978 to 1982. Dr. Kiener has served on the scientific advisory Boards of KAI Pharmaceuticals Inc., Genocea Biosciences Inc., NKT Therapeutics Inc. and VLST Corporation since 2014.
Age | 63 |
Tenure | 10 years |
Professional Marks | Ph.D |
Phone | 301 961-3400 |
Web | www.sucampo.com |
Sucampo Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of 0.0296 % which means that it generated a profit of $0.0296 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 14.16 %, meaning that it created $14.16 on every $100 dollars invested by stockholders. Sucampo Pharmaceuticals' management efficiency ratios could be used to measure how well Sucampo Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 293.54 M in liabilities with Debt to Equity (D/E) ratio of 740.6, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Sucampo Pharmaceuticals has a current ratio of 5.01, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Sucampo Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Sucampo Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Sucampo Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Sucampo to invest in growth at high rates of return. When we think about Sucampo Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Similar Executives
Showing other executives | EXECUTIVE Age | ||
Hajime Ikeda | Nomura Holdings ADR | N/A | |
Anthony Keathley | Stepstone Group | 42 | |
Jennifer Ishiguro | Stepstone Group | N/A | |
Yutaka Nakajima | Nomura Holdings ADR | N/A | |
Yuji Nakata | Nomura Holdings ADR | 59 | |
Valeria Pompa | HF Sinclair Corp | 52 | |
Heiko Holm | Wizz Air Holdings | N/A | |
Junko Nakagawa | Nomura Holdings ADR | 53 | |
Sachin Wagle | Morgan Stanley | N/A | |
Hiromasa Yamazaki | Nomura Holdings ADR | 55 | |
Chie Toriumi | Nomura Holdings ADR | N/A | |
Lewis ODonald | Nomura Holdings ADR | N/A | |
Michael Pizzi | Morgan Stanley | 49 | |
Toru Ohtsuka | Nomura Holdings ADR | 53 | |
Yasushi Takayama | Nomura Holdings ADR | 54 | |
Jonathan Raiff | Nomura Holdings ADR | N/A | |
Steven Ashley | Nomura Holdings ADR | N/A | |
Rig Karkhanis | Nomura Holdings ADR | N/A | |
James Boustead | Morgan Stanley | N/A | |
Eiichiro Yamaguchi | Nomura Holdings ADR | 54 | |
Owain Jones | Wizz Air Holdings | N/A |
Management Performance
Return On Equity | 14.16 | |||
Return On Asset | 0.0296 |
Sucampo Pharmaceuticals Leadership Team
Elected by the shareholders, the Sucampo Pharmaceuticals' board of directors comprises two types of representatives: Sucampo Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sucampo. The board's role is to monitor Sucampo Pharmaceuticals' management team and ensure that shareholders' interests are well served. Sucampo Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sucampo Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
Barbara Munder, Independent Director | ||
Peter Pfreundschuh, CFO, Principal Financial Officer | ||
Matthew Donley, Executive VP of HR | ||
Max Donley, Executive Vice President of Human Resources | ||
Peter Kiener, Chief Scientific Officer | ||
Matthias Alder, Executive Vice President - Business Development & Licensing | ||
Daniel Getman, Independent Chairman of the Board | ||
Peter Greenleaf, Chairman and CEO | ||
Silvia Taylor, Senior Vice President - Investor Relations, Public Relations and Corporate Communications | ||
Peter Lichtlen, Chief Medical Officer | ||
Stanley Miele, Sr. VP of Sales and Marketing and President of Sucampo Pharma Americas LLC | ||
Andrew Smith, Principal Accounting Officer | ||
Timothy Walbert, Director | ||
John Johnson, Director | ||
Paul Edick, Director | ||
Alex Driggs, Acting General Counsel, Corporate Secretary | ||
Karen Smith, Director | ||
Robert Spiegel, Director | ||
Maureen OConnell, Independent Director | ||
Thomas Knapp, Executive Vice President Chief Legal Officer and Corporate Secretary |
Sucampo Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Sucampo Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 14.16 | |||
Return On Asset | 0.0296 | |||
Profit Margin | 7.80 % | |||
Operating Margin | 30.77 % | |||
Current Valuation | 1.05 B | |||
Shares Outstanding | 47.09 M | |||
Shares Owned By Insiders | 35.13 % | |||
Shares Owned By Institutions | 82.48 % | |||
Number Of Shares Shorted | 4.59 M | |||
Price To Earning | (2.77) X |
Currently Active Assets on Macroaxis
LTC | Litecoin | |
STETH | Staked Ether | |
LINK | Chainlink | |
XLM | Stellar | |
CRO | Cronos |
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Other Consideration for investing in Sucampo Stock
If you are still planning to invest in Sucampo Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Sucampo Pharmaceuticals' history and understand the potential risks before investing.
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk |